FDA approval of Icotyde covers the treatment of adults and adolescents with moderate-to-severe plaque psoriasis. This once-daily pill, developed by partners Johnson & Johnson and Protagonist Therapeutics, offers an easier dosing option compared to injectables and is projected to become a blockbuster seller across several immunological indications.
The post J&J Gets FDA Nod for Plaque Psoriasis Pill Positioned to Compete With Injectables appeared first on MedCity News.
